Видео ютуба по тегу Drug Substance Evaluation

FDA's Center for Drug Evaluation and Research's (CDER) Small Business and Industry Assistance (SBIA)
FDA's Center for Drug Evaluation and Research's (CDER) Small Business and Industry Assistance (SBIA)
Bowen.M_OTH5352 Diagnosis Assessment Model Presentation
Bowen.M_OTH5352 Diagnosis Assessment Model Presentation
2022 4 12 The Confusing Picture of Psychotic Disorders Evaluation and Treatment
2022 4 12 The Confusing Picture of Psychotic Disorders Evaluation and Treatment
New Nitazene Data – Ongoing Evaluation of an Emerging Threat
New Nitazene Data – Ongoing Evaluation of an Emerging Threat
Evaluation | 2.1.9 | Drug Substance | 2.1 | ICH Q1A Stability Guideline | Urdu
Evaluation | 2.1.9 | Drug Substance | 2.1 | ICH Q1A Stability Guideline | Urdu
FDA Advancing Generic Drugs 2025: Pharm/Tox for the Safety Evaluation of Nitrosamine Impurities
FDA Advancing Generic Drugs 2025: Pharm/Tox for the Safety Evaluation of Nitrosamine Impurities
FDA Advancing Generic Drugs 2025: Potential Pitfalls in Nitrosamine Risk Assessment and Control
FDA Advancing Generic Drugs 2025: Potential Pitfalls in Nitrosamine Risk Assessment and Control
Approaches for Sensory Evaluation of Medicine Palatability
Approaches for Sensory Evaluation of Medicine Palatability
CHEMICAL EVALUATION OF CRUDE DRUG
CHEMICAL EVALUATION OF CRUDE DRUG
Week 11: Lecture 53: Quantitative Evaluation of Herbal Drugs Using Chromatographic Methods (Part 2)
Week 11: Lecture 53: Quantitative Evaluation of Herbal Drugs Using Chromatographic Methods (Part 2)
Week 11: Lecture 55: Quantitative Evaluation of Herbal Drugs Using Biological Methods
Week 11: Lecture 55: Quantitative Evaluation of Herbal Drugs Using Biological Methods
Week 11: Lecture 52: Quantitative Evaluation of Herbal Drugs Using Chromatographic Methods (Part 1)
Week 11: Lecture 52: Quantitative Evaluation of Herbal Drugs Using Chromatographic Methods (Part 1)
Оценка риска элементарных примесей (EIRA) в фармацевтической промышленности
Оценка риска элементарных примесей (EIRA) в фармацевтической промышленности
Stability Study ICH Guidelines Q1A, Q1B & Q1C | Stability approach | Stress testing | Photostability
Stability Study ICH Guidelines Q1A, Q1B & Q1C | Stability approach | Stress testing | Photostability
ASCP 2025—Practical Considerations for the Evaluation of Physical Dependence and Drug Withdrawal
ASCP 2025—Practical Considerations for the Evaluation of Physical Dependence and Drug Withdrawal
GDF2025 - D2S12- Common Quality Major Deficiencies in Abbreviated New Drug Applications (ANDAs)
GDF2025 - D2S12- Common Quality Major Deficiencies in Abbreviated New Drug Applications (ANDAs)
GDF2025-D2S11- Common Deficiencies in Drug Master Files (DMFs)
GDF2025-D2S11- Common Deficiencies in Drug Master Files (DMFs)
FDA Generic Drugs Forum 2025: Common (OPQ) Deficiencies in Abbreviated New Drug Applications (ANDAs)
FDA Generic Drugs Forum 2025: Common (OPQ) Deficiencies in Abbreviated New Drug Applications (ANDAs)
Что такое критерии ASAM? — Разум превыше содержания
Что такое критерии ASAM? — Разум превыше содержания
Key Drug Addiction Counseling Skills & Techniques - Client Assessment
Key Drug Addiction Counseling Skills & Techniques - Client Assessment
Herbal Drug Technology | Evaluation of Drugs | Unit-4 Part-1 | B Pharm 6th Sem
Herbal Drug Technology | Evaluation of Drugs | Unit-4 Part-1 | B Pharm 6th Sem
Ensuring Safety in Drug Development: Toxicological Risk Assessment | Dr. Raquel Bou
Ensuring Safety in Drug Development: Toxicological Risk Assessment | Dr. Raquel Bou
BE and Drug Product Assessment | Bioequivalence #regulatoryaffairs #mpharm #bpharm #bioequivalence
BE and Drug Product Assessment | Bioequivalence #regulatoryaffairs #mpharm #bpharm #bioequivalence
Quality By Design Risk Assessment for Drug Substance/API
Quality By Design Risk Assessment for Drug Substance/API
Plan Pass Perfect | Alcohol Drug Evaluation DUI
Plan Pass Perfect | Alcohol Drug Evaluation DUI